Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Halberd Corp HALB

Halberd Corporation is a holding company. The Company is engaged in the acquisition vehicle for established businesses. It is also developing treatments for neurodegenerative diseases, such as post-traumatic stress disorder/chronic traumatic encephalopathy (PTSD/ CTE), Alzheimer’s disease and Parkinson’s disease. It has two issued patents and four provisional patent applications related to the... see more

Add To Watchlist

Recent & Breaking News (OTCPK:HALB)

Halberd Corp. Designated as a BREAKOUT Stock to Watch in Investor Publications

Accesswire May 10, 2021

Halberd Corporation Appoints New Chief Technical Officer to Optimize Upcoming Experiments On Radio Frequency and Laser Eradication of Disease

Accesswire May 4, 2021

Halberd Corporation Files International Patent Cooperation Treaty (PCT) Application on Treating and Curing Covid-19 Infection Utilizing a Laser

Accesswire April 26, 2021

Halberd Antibodies Shown To Be Effective Against Multiple Covid-19 Mutations

Accesswire April 21, 2021

Halberd Corporation Moves Radio Frequency (RF) Disease Elimination Effort Forward with the Addition of Youngstown State University (YSU) and Dr. William G. Sturrus

Accesswire April 19, 2021

Epidemiologic Solutions Corporation (ESC), an IRS Approved, Qualified Public Charity, Announces Its Funding for Its "Pain-Free-Veterans" Initiative

Newsfile April 14, 2021

Halberd Corporation Files International Patent Cooperation Treaty (PCT) Application on Covid-19 Inflammatory Cytokine Storm Treatment

Accesswire April 12, 2021

Halberd Corporation CEO Letter

Accesswire April 6, 2021

Halberd Corporation's Scientific Breakthrough: Conjugating Metallic Particles to SARS-CoV-2 and E. Coli Antigens

Accesswire March 30, 2021

Halberd Corporation Completes Compilation of Medical Articles in Support of Nutraceuticals in Their VITA-SHIELD-MAX(TM) Immune Booster

Accesswire March 23, 2021

Halberd Corporation Files International Patent Cooperation Treaty (PCT) Application Covering Extracorporeal Treatment of COVID-19 and Other Medical Maladies

Accesswire March 18, 2021

Halberd Corporation Starts VITA-SHIELD-MAX(TM) Immunity Boosting Nutraceutical Production

Accesswire March 16, 2021

Halberd Corporation Files VITA-SHIELD-MAX(TM) Trademark for Immunity Boosting Nutraceutical

Accesswire March 11, 2021

Halberd's CEO on The Stock Day Podcast Breaking Down 20X Neutralizing Affinity SARS-COV-2 Antibody

Newsfile March 9, 2021

Halberd Corporation's CEO Interviewed on "The Stock Day Podcast" - Focus on Halberd's New 20x Affinity Neutralizing SARS-COV-2 Antibody

Accesswire March 9, 2021

Epidemiologic Solutions Corporation (ESC), an IRS Approved, Qualified Public Charity, Announces Its Commitment of $2,000,000 to Halberd Corporation Research Endeavors (HALB), as Its Initial Step Toward Eradicating Disease

Newsfile March 8, 2021

This Week on MoneyTV with Donald Baillargeon, 3/5

Accesswire March 5, 2021

Halberd's 2nd Proprietary Antibody Against SARS-COV-2 Spike Protein Demonstrates Neutralizing Affinity 20 Times Greater

Accesswire March 2, 2021

Halberd Collaborates with GreenBioAZ, Inc. for the Development of its Patent Pending Radio Frequency Technology to Eliminate Disease Pathogens

Accesswire February 16, 2021

Halberd Corporation's CEO Interviewed on The Stock Day Podcast and on MoneyTV

Accesswire February 1, 2021